SHRARE Launches The Rare Assembly Grant

SHRARE Technology announces the inaugural Rare Assembly Grant, a program created to identify promising rare-disease research and help transform it into a structured, protectable and potentially licensable Medical Product Candidate (MPC).

Open to: Technology Transfer Offices, universities and research institutes, researchers and inventors, physicians and physician-scientists, professors and academic laboratories, early-stage biotech companies, rare-disease foundations, and patient-led research organizations.

You do not need a complete therapeutic program. SHRARE is also looking for individual fragments of research — incomplete in isolation, decisive when connected. A fragment may be: a formulation, a patent or application, an unpublished invention, a molecule, a therapeutic combination, a biomarker, a delivery technology, a clinical observation, a case series, a disease model, a diagnostic method, a dataset, a mechanism of action, a discontinued development program, or an academic discovery without a development partner.

A formulation may unlock an existing molecule. A patent may protect a strategy no one owns. A biomarker may make a trial possible. A clinical observation may reveal a new indication. A discontinued program may deserve to be reassembled rather than abandoned.

SHRARE calls this Assembly Intelligence™: identifying fragmented scientific value and connecting it with the evidence, IP, regulatory strategy, development capability and people required to create an executable therapeutic opportunity. The selected project enters a dedicated MPC Assembly Program.

The award — CHF 50,000 in SHRARE service credits (Assembly Intelligence™, scientific, IP, regulatory and pharmaceutical-development support), delivered as a fixed lump sum of services rather than cash. Structure agreed with the selected researcher, institution, foundation or company.

How to participate. Apply via the Rare Assembly Grant landing page — primarily by nomination and invitation, but open submissions are welcome too. Have ready: the rare disease, the research or fragment, the evidence you have, its potential therapeutic relevance, existing publications or IP, what you believe is missing, and why SHRARE could help assemble it. Confidential information only after a confidentiality agreement.

Rare-disease research does not always fail because the science is absent. Sometimes the science exists but remains fragmented. Assembled correctly, it may become the beginning of a medicine. Your research may be a fragment. It may also be the missing piece.